Quick Answer
Praxis Precision Medicines, Inc. reported R&D Expense of $267.12 million for fiscal year 2025.
Praxis Precision Medicines, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $267.12M | +75.3% |
| 2024 | $152.41M | +75.7% |
| 2023 | $86.77M | -44.0% |
| 2022 | $155.04M | +28.9% |
| 2021 | $120.26M | +167.4% |
| 2020 | $44.98M | +52.2% |
| 2019 | $29.56M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $65.80M | +57.1% | +4.4% |
| June 30, 2025 | $63.01M | +131.1% | +3.6% |
| March 31, 2025 | $60.81M | +125.3% | +45.2% |
| September 30, 2024 | $41.88M | +142.6% | +53.6% |
| June 30, 2024 | $27.26M | +6.4% | +1.0% |
| March 31, 2024 | $26.98M | +5.8% | +56.3% |
| September 30, 2023 | $17.26M | -43.3% | -32.6% |
| June 30, 2023 | $25.61M | -41.3% | +0.4% |
- Praxis Precision Medicines, Inc. showed an increase of +75.3% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Praxis Precision Medicines, Inc.’s r&d expense has grown by 803.7% (from $29.56 million to $267.12 million).
- The most recent figure is from Praxis Precision Medicines, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: